Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial

PURPOSE: Report the efficacy and safety of pasireotide sc in patients with Cushing’s disease during an open-ended, open-label extension to a randomized, double-blind, 12-month, Phase III study. METHODS: 162 patients entered the core study. 58 patients who had mean UFC ≤ ULN at month 12 or were benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Schopohl, Jochen, Gu, Feng, Rubens, Robert, Van Gaal, Luc, Bertherat, Jérôme, Ligueros-Saylan, Monica, Trovato, Andrew, Hughes, Gareth, Salgado, Luiz R., Boscaro, Marco, Pivonello, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560758/
https://www.ncbi.nlm.nih.gov/pubmed/25537481
http://dx.doi.org/10.1007/s11102-014-0618-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560758/
https://www.ncbi.nlm.nih.gov/pubmed/25537481
http://dx.doi.org/10.1007/s11102-014-0618-1

Ejemplares similares